BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

545 related articles for article (PubMed ID: 33972241)

  • 1. Epidemiology of Carbapenem Resistance Determinants Identified in Meropenem-Nonsusceptible
    Kazmierczak KM; Karlowsky JA; de Jonge BLM; Stone GG; Sahm DF
    Antimicrob Agents Chemother; 2021 Jun; 65(7):e0200020. PubMed ID: 33972241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiology of Resistance Determinants Identified in Meropenem-Nonsusceptible
    Estabrook M; Muyldermans A; Sahm D; Pierard D; Stone G; Utt E
    Antimicrob Agents Chemother; 2023 May; 67(5):e0140622. PubMed ID: 37074173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meropenem-Vaborbactam Activity against U.S. Multidrug-Resistant
    Shortridge D; Kantro V; Castanheira M
    Microbiol Spectr; 2023 Feb; 11(1):e0450722. PubMed ID: 36622238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of ceftazidime/avibactam and comparators against carbapenemase-producing Enterobacterales and Pseudomonas aeruginosa isolates collected globally between 2016 and 2018.
    Kiratisin P; Kazmierczak K; Stone GG
    J Glob Antimicrob Resist; 2021 Dec; 27():132-141. PubMed ID: 34478880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meropenem-Vaborbactam Activity against Carbapenem-Resistant
    Castanheira M; Doyle TB; Kantro V; Mendes RE; Shortridge D
    Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31712207
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Wise MG; Karlowsky JA; Hackel MA; Takemura M; Yamano Y; Echols R; Sahm DF
    Microb Drug Resist; 2023 Aug; 29(8):360-370. PubMed ID: 37253158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal analysis of ESBL and carbapenemase carriage among Enterobacterales and Pseudomonas aeruginosa isolates collected in Europe as part of the International Network for Optimal Resistance Monitoring (INFORM) global surveillance programme, 2013-17.
    Kazmierczak KM; de Jonge BLM; Stone GG; Sahm DF
    J Antimicrob Chemother; 2020 May; 75(5):1165-1173. PubMed ID: 32040168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distribution of β-lactamases and emergence of carbapenemases co-occurring Enterobacterales isolates with high-level antibiotic resistance identified from patients with intra-abdominal infection in the Asia-Pacific region, 2015-2018.
    Chen YC; Chen WY; Hsu WY; Tang HJ; Chou Y; Chang YH; Chen CC; Chuang YC; Chang TH
    J Microbiol Immunol Infect; 2022 Dec; 55(6 Pt 2):1263-1272. PubMed ID: 34330663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular epidemiology of clinical isolation of carbapenem-resistant Enterobacterales and application of carbapenemase inhibitor enhancement test.
    Li H; Zhong Y; Yan Q; Liu W; Liang X
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Aug; 48(8):1210-1216. PubMed ID: 37875361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme.
    Pfaller MA; Huband MD; Mendes RE; Flamm RK; Castanheira M
    Int J Antimicrob Agents; 2018 Aug; 52(2):144-150. PubMed ID: 29510189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microbiology of Meropenem-Vaborbactam: A Novel Carbapenem Beta-Lactamase Inhibitor Combination for Carbapenem-Resistant Enterobacterales Infections.
    Bhowmick T; Weinstein MP
    Infect Dis Ther; 2020 Dec; 9(4):757-767. PubMed ID: 33017041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in Latin America: SMART 2018‒2020.
    Karlowsky JA; Lob SH; Siddiqui F; Pavia J; DeRyke CA; Young K; Motyl MR; Sahm DF
    Braz J Infect Dis; 2023; 27(3):102775. PubMed ID: 37169345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Investigation of carbapenemases in carbapenem-resistant Escherichia coli and Klebsiella pneumoniae strains isolated in 2014 in Turkey].
    Çakar A; Akyön Y; Gür D; Karatuna O; Öğünç D; Özhak Baysan B; Çöplü N; Çağatay M; Kılıç A; Baysallar M; Bakıcı Z; Çelik C; Gülay Z; Aydemir Ş; Tünger A; Kılıç H; Erçal BD; Aşçı Toraman Z; Zer Y; Büyüktaş A; Ay S; Aktaş Z; Kayacan Ç; Bayramoğlu G; Aydın F; Dündar D; Hasdemir U; Ayaş R; Yanık K; Günaydın M; Güdücüoğlu H; Parlak M
    Mikrobiyol Bul; 2016 Jan; 50(1):21-33. PubMed ID: 27058326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016-2018).
    Piérard D; Stone GG
    BMC Infect Dis; 2021 Jun; 21(1):600. PubMed ID: 34162341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of aztreonam-avibactam against Enterobacterales isolates collected in Latin America, Africa/Middle East, Asia, and Eurasia for the ATLAS Global Surveillance Program in 2019-2021.
    Wise MG; Karlowsky JA; Mohamed N; Kamat S; Sahm DF
    Eur J Clin Microbiol Infect Dis; 2023 Sep; 42(9):1135-1143. PubMed ID: 37526796
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Karlowsky JA; Hackel MA; Wise MG; Six DA; Uehara T; Daigle DM; Cusick SM; Pevear DC; Moeck G; Sahm DF
    Antimicrob Agents Chemother; 2023 Jan; 67(1):e0128122. PubMed ID: 36541767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa isolates collected in Latin America as part of the ATLAS global surveillance program, 2017-2019.
    Karlowsky JA; Kazmierczak KM; Valente MLNF; Luengas EL; Baudrit M; Quintana A; Irani P; Stone GG; Sahm DF
    Braz J Infect Dis; 2021; 25(6):101647. PubMed ID: 34774471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating NG-Test CARBA 5 Multiplex Immunochromatographic and Cepheid Xpert CARBA-R Assays among Carbapenem-Resistant
    Huang YT; Kuo YW; Lee NY; Tien N; Liao CH; Teng LJ; Ko WC; Hsueh PR;
    Microbiol Spectr; 2022 Feb; 10(1):e0172821. PubMed ID: 35019772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of aztreonam-avibactam against Enterobacterales resistant to recently approved beta-lactamase inhibitor combinations collected in Europe, Latin America, and the Asia-Pacific Region (2020-2022).
    Sader HS; Carvalhaes CG; Kimbrough JH; Mendes RE; Castanheira M
    Int J Antimicrob Agents; 2024 Apr; 63(4):107113. PubMed ID: 38354826
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Karlowsky JA; Kazmierczak KM; Bouchillon SK; de Jonge BLM; Stone GG; Sahm DF
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.